Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the US

Cidara Therapeutics, Inc. announced that it has submitted a New Drug Application (NDA) to the US FDA for rezafungin for the treatment of candidemia and invasive candidiasis.